
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| CONTRAVE | Nalpropion Pharmaceuticals | N-200063 RX | 2014-09-10 | 1 products, RLD, RS |
Brand Name | Status | Last Update |
|---|---|---|
| contrave | New Drug Application | 2025-05-07 |
| naltrexone | unapproved drug other | 2018-03-19 |
| naltrexone hydrochloride | ANDA | 2025-10-02 |
| naltrexone hyrdochloride | ANDA | 2009-07-21 |
| trexall | ANDA | 2021-04-30 |
| vivitrol | New Drug Application | 2024-05-22 |
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Bupropion Hydrochloride / Naltrexone Hydrochloride, Contrave, Nalpropion | |||
| 10231964 | 2034-07-02 | U-1583 | |
| 10828294 | 2034-07-02 | U-1583 | |
| 10835527 | 2034-07-02 | U-1583 | |
| 9633575 | 2033-06-25 | U-1583 | |
| 10403170 | 2033-06-05 | U-1583 | |
| 11139056 | 2033-06-05 | U-1583 | |
| 9248123 | 2032-01-13 | U-1808 | |
| 11033543 | 2031-01-10 | U-1583 | |
| 8916195 | 2030-02-02 | U-1639 | |
| 11324741 | 2029-05-29 | U-1583 | |
| 8088786 | 2029-02-03 | DP | |
| 8318788 | 2027-11-08 | U-1584 | |
| 8722085 | 2027-11-08 | U-1585 | |
| 9125868 | 2027-11-08 | U-1585 | |
| 10307376 | 2027-11-08 | U-1585 | |
| 9107837 | 2027-06-04 | U-1639 | |
| 7375111 | 2025-03-26 | DP | |
| 7462626 | 2024-07-20 | U-1583 | |
| 8815889 | 2024-07-20 | U-1586 | |
| 11278544 | 2024-04-21 | U-1583 | |
| Morphine Sulfate / Naltrexone Hydrochloride, Embeda, Alpharma Pharms | |||
| 8623418 | 2029-11-07 | U-1640 | |
| 7815934 | 2027-12-12 | DP | |
| 7682633 | 2027-06-19 | U-1510 | |
| 7682634 | 2027-06-19 | DP | |
| 8158156 | 2027-06-19 | U-1510 | |
| 8846104 | 2027-06-19 | DP | |
| 8877247 | 2027-06-19 | DP | |
| 8685443 | 2025-07-03 | U-1508 | |
| 8685444 | 2025-07-03 | DP | |
| Naltrexone, Vivitrol, Alkermes | |||
| 7919499 | 2029-10-15 | U-1123, U-1124 | |
Code | Description |
|---|---|
| G2073 | Medication assisted treatment, naltrexone; weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a medicare-enrolled opioid treatment program) |
| J2212 | Injection, methylnaltrexone, 0.1 mg |
| J2315 | Injection, naltrexone, depot form, 1 mg |

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Obesity | D009765 | EFO_0001073 | E66.9 | — | 3 | 6 | 2 | — | 11 |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Overweight | D050177 | — | E66.3 | — | 3 | 6 | — | — | 9 |
| Body weight | D001835 | EFO_0004338 | — | — | — | 1 | — | — | 1 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | 1 | — | — | 1 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Depression | D003863 | — | F33.9 | — | 1 | — | — | — | 1 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | — | 1 | — | — | — | 1 |
| Tobacco use disorder | D014029 | — | F17 | — | 1 | — | — | — | 1 |
| Obsessive-compulsive disorder | D009771 | EFO_0004242 | F42 | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 2 | — | — | — | — | 2 |
| Drug common name | Naltrexone |
| INN | naltrexone |
| Description | Naltrexone is an organic heteropentacyclic compound that is naloxone substituted in which the allyl group attached to the nitrogen is replaced by a cyclopropylmethyl group. A mu-opioid receptor antagonist, it is used to treat alcohol dependence. It has a role as a mu-opioid receptor antagonist, a central nervous system depressant, an environmental contaminant, a xenobiotic and an antidote to opioid poisoning. It is an organic heteropentacyclic compound, a morphinane-like compound and a member of cyclopropanes. It is a conjugate base of a naltrexone(1+). |
| Classification | Small molecule |
| Drug class | narcotic agonists/antagonists (normorphine type) |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5 |
| PDB | — |
| CAS-ID | 16590-41-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL19019 |
| ChEBI ID | 7465 |
| PubChem CID | 5360515 |
| DrugBank | DB00704 |
| UNII ID | 5S6W795CQM (ChemIDplus, GSRS) |













